AdvanCell Secures $315 Million in Series D Funding
AdvanCell, a clinical-stage radiopharmaceutical company known for its work on targeted alpha therapies, has closed a $315 million Series D funding round. The investment was led by Ally Bridge Group, with participation from a diverse group of investors including Alpha Wave, Bain Capital Life Sciences, Fidelity Management & Research Company, T. Rowe Price Associates, Inc., Eventide Asset Management, Velosity Capital, and others.
Company Overview
AdvanCell is actively developing a pipeline of innovative targeted alpha therapies, which are designed to selectively target and treat cancer cells while minimizing damage to healthy tissues. The company is vertically integrated, managing everything from isotope supply to automated manufacturing, which allows it to streamline the development and delivery of its therapies.
Funding Round Details
The latest funding round was oversubscribed, reflecting strong interest in AdvanCell's promising technology and business model. The round was co-led by Alpha Wave, and included both new and existing investors. Notably, healthcare giants such as Eli Lilly and Company, Sanofi Ventures, and SV Health Investors also participated.
Use of Funds
The $315 million raised will be directed towards multiple strategic initiatives. A significant portion is earmarked for advancing AdvanCell's leading program, ADVC001, which is currently in Phase 2 clinical trials for metastatic prostate cancer. This therapy uses AdvanCell's proprietary Lead-212 technology to deliver targeted alpha radiation to tumor cells. The funds will also support the expansion of the company's Lead-212 platform, enhance isotope supply, and boost U.S. manufacturing capabilities.
Leadership Insights
Philina Lee, the Chief Executive Officer of AdvanCell, commented on the funding round's impact, emphasizing that it marks a significant milestone in the company's journey. "This financing enables us to advance our lead program and expand our pipeline of targeted therapies," Lee noted.
Strategic Board Appointments
With the closing of this funding round, AdvanCell also announced new appointments to its Board of Directors. Andrew Lam from Ally Bridge Group and Nik Economopoulos from Alpha Wave will join the board, bringing their expertise in healthcare investments to the company.
Conclusion
The substantial investment in AdvanCell underscores the growing interest in targeted alpha therapies as a promising approach to cancer treatment. With this new capital, AdvanCell is well-positioned to accelerate its clinical programs and expand its technological capabilities, potentially offering new hope to patients with difficult-to-treat cancers.